Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palatin

0.2310
+0.01105.00%
Post-market: 0.2174-0.0136-5.89%18:28 EDT
Volume:3.68M
Turnover:784.90K
Market Cap:6.50M
PE:-0.16
High:0.2310
Open:0.1910
Low:0.1910
Close:0.2200
Loading ...

Palatin Technologies Inc - Phase 2 Trial Showed Significant Weight Loss With Bremelanotide and Tirzepatide

THOMSON REUTERS
·
17 Apr

Palatin Technologies Inc - Ind Filings Expected by End of Q4 2025

THOMSON REUTERS
·
17 Apr

Palatin Technologies Inc - Low-Dose Bremelanotide Prevented Appetite Rebound After Tirzepatide Cessation

THOMSON REUTERS
·
17 Apr

Top Premarket Gainers

MT Newswires Live
·
14 Apr

Palatin appeals NYSE American notice of delisting

TIPRANKS
·
14 Apr

BRIEF-Palatin Appeals NYSE American Notice Of Delisting

Reuters
·
14 Apr

Palatin Appeals NYSE American Notice of Delisting

PR Newswire
·
14 Apr

Palatin Technologies Gets Delisting Notice from NYSE American, Plans to Appeal

MT Newswires Live
·
11 Apr

BRIEF-Palatin Technologies, Inc. Announces Receipt Of NYSE American Notice Of Delisting And Intention To Appeal

Reuters
·
11 Apr

Palatin receives NYSE American notice of delisting, plans to appeal

TIPRANKS
·
11 Apr

Palatin Technologies, Inc. Announces Receipt of Nyse American Notice of Delisting and Intention to Appeal

THOMSON REUTERS
·
11 Apr

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

PR Newswire
·
11 Apr

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

PR Newswire
·
10 Apr

BRIEF-Palatin Technologies Files Offering Up To 17.3 Million Shares Of Common Stock Together With Series F Common Stock Purchase Warrants

Reuters
·
01 Apr

Palatin Technologies Files Offering up to 17.3 Mln Shares of Common Stock Together With Series F Common Stock Purchase Warrants

THOMSON REUTERS
·
01 Apr

Palatin says BMT-801 Phase 2 obesity study met primary endpoint

TIPRANKS
·
31 Mar

Palatin Technologies Inc - Ind Applications Planned for 4Q25, Clinical Data Expected 1H26

THOMSON REUTERS
·
31 Mar

Palatin Announces Mc4r Agonist Bremelanotide Co-Administered With Glp-1/Gip Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

THOMSON REUTERS
·
31 Mar

Palatin Technologies' Ulcerative Colitis Drug Candidate Shows Positive Results in Phase 2 Study

MT Newswires Live
·
28 Mar

BRIEF-Palatin Announces Positive Topline Results From Phase 2 Ulcerative Colitis (UC) Study Of Oral Melanocortin-1 Receptor Agonist Pl8177

Reuters
·
28 Mar